Azomax (Azithromycin) is an azalide, derived, from the macrolide class of antibiotics. Azithromycin demonstrates activity in vitro, against a wide range of Gram-positive and Gram-negative bacteria including Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes (Group A) and other Streptococcal species; Haemophilus influenzae and para- influenzae; Moraxella catarrhalis; anaerobes including Bacteroids fragilis; Escherichia coli; Bordetella pertussis; Bordetella parapertussis; Borrelia burgdorferi; Haemophilus ducreyi; Neisseria gonorrhoeae and Chlamydia trachomatis. Azithromycin also demonstrates in-vitro activity against Legionella pneumophila, Mycoplasma pneumoniae and hominis, Campylobacter sp,Toxoplasma gondii and Treponema pallidum.
Following oral administration in humans, Azomax is widely distributed throughout the body; bioavailability is approximately 37%. The time taken to reach peak plasma levels is 2-3 hours. Plasma terminal elimination half-life closely reflects the tissue depletion half-life of 2 to 4 days. Kinetic studies have shown markedly higher azithromycin levels in tissue than in plasma (upto 50 times the maximum observed concentration in plasma) indicating that the drug is highly tissue bound. Concentrations in target tissue such as lungs, tonsils and prostate exceed the MIC90 for likely pathogens after a single dose of 500mg.